Alzheimer's Disease: Early Diagnosis and Promising Treatments Explored on The Naked Scientists

Episode snapshot

The Naked Scientists team examine Alzheimer’s disease, its biology and the growing societal burden, with a focus on emerging diagnostic and therapeutic avenues.

• Alzheimer's as a leading cause of dementia with rising global cases and high care costs
• Early diagnosis through AI-based brain imaging and blood biomarkers
• Antibody therapies Donanemab and Lecanimab that reduce brain amyloid and slow progression
• Importance of clinician involvement, caregiver support, and public health investment

Overview

The podcast investigates Alzheimer's disease as a major public health challenge, highlighting its prevalence, the aging global population, and the rising costs of care. With projections suggesting hundreds of thousands more cases by mid-century, the discussion emphasizes the need for faster diagnosis and new treatments that can meaningfully alter the disease trajectory.

Personal lived experience and public health context

One segment centers on a caregiver’s experience living with a family member who has Alzheimer's disease. The discussion underscores the emotional and financial toll of long-term care and the sense that formal support systems often lag behind the needs of patients and their families. The conversation also points to the UK as a case study in dementia care costs and policy responses, noting that dementia is a leading cause of death and a major driver of health and social care spending.

Biology and risk factors

Researchers explain that Alzheimer's disease is driven by the accumulation of amyloid protein plaques, followed by tau protein tangles that damage neurons. Neuroinflammation and immune cell dysfunction are described as additional components of the disease process. While aging remains the biggest risk factor, modifiable factors such as air pollution, smoking, and diet influence risk, and women appear to have a higher incidence of Alzheimer’s disease even after accounting for age. The brain changes can begin 15 to 20 years before symptoms, making early identification crucial for any effective intervention.

Economic implications and policy guidance

The podcast discusses how dementia care costs could double by 2050 due to population aging, and how informal care and social care costs contribute to the burden. Investment in research, diagnostics, and prevention is framed as a strategic best buy that could yield large returns by delaying onset and reducing the duration of severe impairment, thereby easing the burden on the NHS and social care systems.

Diagnosing Alzheimer's earlier: AI and biomarkers

Tim Rittman and colleagues are using artificial intelligence to identify brain changes years before clinical onset. Using data from the UK Biobank, the team trained an algorithm to detect subtle brain shrinkage linked to Alzheimer’s disease, applied it to healthy individuals aged 45–65, and identified a subset who may be at elevated risk. While cognitive tests alone may miss early signals, imaging and blood biomarkers could improve predictive accuracy. Blood tests targeting tau in plasma are highlighted as a promising, increasingly feasible tool that could accompany imaging to support early diagnosis in memory clinics.

Therapies and the road ahead

The core therapeutic focus is on antibodies that target amyloid plaques in the brain. The podcast explains that infused antibodies can reduce amyloid burden and have shown clinical benefit, though the magnitude of delay in disease progression has varied. Side effects, including immune-related events, are discussed as a reminder that ongoing development is needed to optimize safety and efficacy. Tau-targeted strategies and combination approaches are also considered as essential components of a multi-faceted treatment paradigm. There is cautious optimism that these therapies could mark a turning point in the management of Alzheimer’s disease, especially if deployed earlier in the disease course.

Diet, biomarkers, and clinical pathways